{"id":45409,"date":"2022-06-23T12:01:59","date_gmt":"2022-06-23T10:01:59","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/"},"modified":"2022-06-23T12:01:59","modified_gmt":"2022-06-23T10:01:59","slug":"dem-biopharma-launches-with-70-million-financing","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/","title":{"rendered":"DEM BioPharma Launches with $70 Million Financing"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Company will pursue untapped opportunities in the field of innate immune system checkpoints to eliminate cancer<\/i>\n<\/p>\n<p class=\"bwalignc\">\n<i>Proprietary platform leverages CRISPR screening and macrophage biology to systematically discover and drug \u201c<b>don\u2019t eat me<\/b>\u201d (DEM) and \u201c<b>eat me<\/b>\u201d (EM) signals<\/i>\n<\/p>\n<p>CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;DEM BioPharma, Inc. (DEM Bio), an immuno-oncology company developing therapies that target novel innate immune system checkpoints to eliminate cancer, today announced its initial $70 million financing led by founding investor <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.longwoodfund.com%2F&amp;esheet=52759018&amp;newsitemid=20220623005116&amp;lan=en-US&amp;anchor=Longwood+Fund&amp;index=1&amp;md5=4988f998307bbcc1b830bfa8a824c46e\" rel=\"nofollow noopener\" shape=\"rect\">Longwood Fund<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.altapartners.com%2F&amp;esheet=52759018&amp;newsitemid=20220623005116&amp;lan=en-US&amp;anchor=Alta+Partners&amp;index=2&amp;md5=ca72332de8cefcfd4ba3b9f006d634b1\" rel=\"nofollow noopener\" shape=\"rect\">Alta Partners<\/a>, with additional participation from <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.insightpartners.com%2F&amp;esheet=52759018&amp;newsitemid=20220623005116&amp;lan=en-US&amp;anchor=Insight+Partners&amp;index=3&amp;md5=777395a470757ef038d834dbb0aadf2c\" rel=\"nofollow noopener\" shape=\"rect\">Insight Partners<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pfizer.com%2Fabout%2Fpartners%2Fventure-investments&amp;esheet=52759018&amp;newsitemid=20220623005116&amp;lan=en-US&amp;anchor=Pfizer+Ventures&amp;index=4&amp;md5=16c46c6f57acb12e1344e94f3e4e0617\" rel=\"nofollow noopener\" shape=\"rect\">Pfizer Ventures<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astellasventure.com%2F&amp;esheet=52759018&amp;newsitemid=20220623005116&amp;lan=en-US&amp;anchor=Astellas+Venture+Management&amp;index=5&amp;md5=d3c56c67739a136fc8238827261874c4\" rel=\"nofollow noopener\" shape=\"rect\">Astellas Venture Management<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.emersoncollective.com%2F&amp;esheet=52759018&amp;newsitemid=20220623005116&amp;lan=en-US&amp;anchor=Emerson+Collective&amp;index=6&amp;md5=e8db041375eef3b6ed5273f51e7b6e5a\" rel=\"nofollow noopener\" shape=\"rect\">Emerson Collective<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.utokyo-ipc.co.jp%2Fen%2F&amp;esheet=52759018&amp;newsitemid=20220623005116&amp;lan=en-US&amp;anchor=UTokyo+Innovation+Platform&amp;index=7&amp;md5=4de7f78e4cff0d8f3461246c3f5f7593\" rel=\"nofollow noopener\" shape=\"rect\">UTokyo Innovation Platform<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.are.com%2Fventure-investments.html&amp;esheet=52759018&amp;newsitemid=20220623005116&amp;lan=en-US&amp;anchor=Alexandria+Venture+Investments&amp;index=8&amp;md5=0a363b4d3f49e8690c7cdb69717ce648\" rel=\"nofollow noopener\" shape=\"rect\">Alexandria Venture Investments<\/a>.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220623005116\/en\/1494351\/5\/DEM_Logo_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220623005116\/en\/1494351\/21\/DEM_Logo_RGB.jpg\"><\/a><\/p>\n<p>\nDEM Bio is pioneering the next generation of immunotherapeutics designed to unleash macrophages and other myeloid effector cells to eliminate tumors by targeting novel \u2018don\u2019t eat me\u2019 (DEM) and \u2018eat me\u2019 (EM) signals on cancer cells and macrophages. The company\u2019s approach builds on the groundbreaking research from its scientific co-founders:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nJonathan Weissman, Ph.D. &#8211; Whitehead Institute, National Academy of Sciences member, HHMI, world leader in genome-wide CRISPR screens;\n<\/li>\n<li>\nMichael Bassik, Ph.D. &#8211; Stanford University, a distinguished biologist in cancer, phagocytes, and CRISPR screening; and\n<\/li>\n<li>\nKipp Weiskopf, M.D., Ph.D. \u2013 Whitehead Fellow and physician at Dana-Farber Cancer Institute, one of the world\u2019s leaders in macrophage and cancer biology.\n<\/li>\n<\/ul>\n<p>\nDEM Bio is focused on accessing the largely untapped opportunity around macrophage biology and innate immune system pathways to discover potent DEM and EM signals on cancers and expand the therapeutic potential of the field beyond the relatively small number of signals targeted by current investigational therapies. The company\u2019s proprietary CHoMP\u2122 platform (Co-culture with Human Myeloid Phagocytes) will be used to identify unexplored DEM and EM signals in a systematic and unbiased manner via inter-cellular CRISPR screening using tumor cells, primary macrophages, and other innate immune effector cells.\n<\/p>\n<p>\nDEM Bio also announced the appointment of Jan Skvarka, former CEO of Trillium Therapeutics (acquired by Pfizer for $2.22 billion in November 2021), as Executive Chairman. As part of the financing, Christoph Westphal, M.D., Ph.D., Founding CEO, DEM Bio, and Founding Partner Longwood Fund; Dan Janney, Managing Partner, Alta Partners; Dylan Morris, Managing Director, Insight Partners; Marie-Claire Peakman, Ph.D., Principal, Pfizer Ventures; and Hiro Kimura, Ph.D., Investment Director, Astellas Venture Management have joined DEM Bio\u2019s <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdembiopharma.com%2F%23directors&amp;esheet=52759018&amp;newsitemid=20220623005116&amp;lan=en-US&amp;anchor=Board+of+Directors&amp;index=9&amp;md5=b763a002122dfbd3adeb2830993497b1\" rel=\"nofollow noopener\" shape=\"rect\">Board of Directors<\/a>.\n<\/p>\n<p>\n\u201cCurrently known DEM signals have been described in an ad hoc manner. DEM Bio\u2019s founders discovered a scalable approach to systematically unlock the potential of innate immune system checkpoints,\u201d noted Dr. Westphal.\n<\/p>\n<p>\n\u201cThis financing from an exceptional group of investors positions us to execute on our ambitious plans to develop the next generation of macrophage checkpoint inhibitors that may revolutionize how we treat cancer,\u201d said Mr. Skvarka.\n<\/p>\n<p>\nDEM Bio has assembled a world-class <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdembiopharma.com%2F%23sab&amp;esheet=52759018&amp;newsitemid=20220623005116&amp;lan=en-US&amp;anchor=Scientific+Advisory+Board&amp;index=10&amp;md5=48724b7599b9fd9ec1ab6283a0c7d81f\" rel=\"nofollow noopener\" shape=\"rect\">Scientific Advisory Board<\/a> consisting of leaders in the field of CRISPR high-throughput screening, immune phagocytes, cancer biology, and therapeutic development, including co-founders Drs. Weissman, Bassik and Weiskopf, Roarke Kamber, Ph.D., Postdoctoral fellow, Genetics, Stanford School of Medicine, Dian Yang, Ph.D., Postdoctoral fellow, Whitehead Institute for Biomedical Research, as well as Kai Wucherpfennig, M.D., Ph.D., Professor and Chair, Dana-Farber Cancer Institute; Dane Wittrup, Ph.D., Professor of Chemical Engineering &amp; Bioengineering, MIT; and Bob Uger, Ph.D., former CSO, Trillium Therapeutics.\n<\/p>\n<p>\n\u201cThe currently known DEM and EM pathways were discovered serendipitously,\u201d said Dr. Bassik. \u201cSimilar to other areas of immunotherapy, there are likely other signals that are more potent and offer better therapeutic targets, but no one has yet taken a systematic approach to identifying those pathways.\u201d\n<\/p>\n<p>\n\u201cBy leveraging cutting-edge functional genomics and macrophage biology, we created the CHoMP platform to discover new DEM\/EM signals in a fully unbiased and systematic way,\u201d said Dr. Weiskopf.\n<\/p>\n<p>\n\u201cCHoMP is a highly differentiated platform built on unique, proprietary CRISPR screening capabilities in primary human cells, enabling DEM Bio to methodically evaluate unexplored DEM\/EM signals,\u201d said Dr. Weissman.\n<\/p>\n<p>\nThe CHoMP platform has identified a number of promising new DEM\/EM signals, including the novel DEM pathway APMAP. In preclinical work, targeting APMAP enhanced tumor cell phagocytosis in multiple cancer cell types and animal cancer models, and demonstrated synergistic effects with a broad range of tumor-binding antibodies.\n<\/p>\n<p>\nDavid Donabedian, Co-founder and start-up CEO of DEM Bio, and Operating Partner, Longwood Fund added, \u201cAPMAP is just one of the promising programs identified using the CHoMP platform, and the encouraging initial data on this pathway has helped validate our differentiated approach to identifying novel, potent DEM\/EM signals. The company plans to use proceeds from this financing to further develop our platform and to advance our portfolio of novel targets towards therapeutic development in oncology.\u201d\n<\/p>\n<p>\n<b>About DEM BioPharma Inc.<\/b>\n<\/p>\n<p>\nDEM Bio is pioneering the next generation of immunotherapeutics that unleash the innate immune system to eliminate tumors by targeting \u2018don\u2019t eat me\u2019 (DEM) and \u2018eat me\u2019 (EM) signals on cancer cells, macrophages and other myeloid effector cells. Founded by Longwood Fund, the company\u2019s approach builds on the groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders: Drs. Jonathan Weissman and Kipp Weiskopf of the Whitehead Institute and Dr. Michael Bassik of Stanford University. The proprietary CHoMP\u2122 platform (Co-culture with Human Myeloid Phagocytes) utilizes CRISPR-based functional genomic screens in human cancer cells and\/or primary macrophages to discover and validate new DEM and EM signals that could profoundly induce and enhance cancer cell elimination through increased phagocytosis.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nKari Watson or Nicholas Chang<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#58;&#x6b;w&#97;&#x74;s&#111;&#x6e;&#64;&#109;&#x61;c&#100;&#x6f;u&#103;&#x61;l&#108;&#x2e;b&#105;&#x6f;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6b;&#119;&#97;t&#x73;&#x6f;&#110;&#64;&#x6d;&#x61;&#99;d&#x6f;&#x75;&#103;a&#x6c;&#x6c;&#46;b&#x69;&#x6f;<\/a> or <a target=\"_blank\" href=\"&#x6d;&#97;&#x69;&#x6c;&#116;&#x6f;&#58;n&#x63;&#104;a&#x6e;&#103;&#64;&#x6d;&#97;c&#x64;&#111;&#x75;&#x67;&#97;&#x6c;&#x6c;&#46;&#x62;&#105;o\" rel=\"nofollow noopener\" shape=\"rect\">&#x6e;&#x63;&#104;&#97;ng&#x40;&#x6d;&#x61;&#99;do&#x75;&#x67;&#x61;&#108;&#108;&#46;&#x62;&#x69;&#x6f;<\/a><br \/>(781) 235-3060\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company will pursue untapped opportunities in the field of innate immune system checkpoints to eliminate cancer Proprietary platform leverages CRISPR screening and macrophage biology to systematically discover and drug \u201cdon\u2019t eat me\u201d (DEM) and \u201ceat me\u201d (EM) signals CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;DEM BioPharma, Inc. (DEM Bio), an immuno-oncology company developing therapies that target novel innate immune &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45409","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DEM BioPharma Launches with $70 Million Financing - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DEM BioPharma Launches with $70 Million Financing - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Company will pursue untapped opportunities in the field of innate immune system checkpoints to eliminate cancer Proprietary platform leverages CRISPR screening and macrophage biology to systematically discover and drug \u201cdon\u2019t eat me\u201d (DEM) and \u201ceat me\u201d (EM) signals CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;DEM BioPharma, Inc. (DEM Bio), an immuno-oncology company developing therapies that target novel innate immune ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-23T10:01:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220623005116\/en\/1494351\/21\/DEM_Logo_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dem-biopharma-launches-with-70-million-financing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dem-biopharma-launches-with-70-million-financing\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"DEM BioPharma Launches with $70 Million Financing\",\"datePublished\":\"2022-06-23T10:01:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dem-biopharma-launches-with-70-million-financing\\\/\"},\"wordCount\":916,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dem-biopharma-launches-with-70-million-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220623005116\\\/en\\\/1494351\\\/21\\\/DEM_Logo_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dem-biopharma-launches-with-70-million-financing\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dem-biopharma-launches-with-70-million-financing\\\/\",\"name\":\"DEM BioPharma Launches with $70 Million Financing - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dem-biopharma-launches-with-70-million-financing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dem-biopharma-launches-with-70-million-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220623005116\\\/en\\\/1494351\\\/21\\\/DEM_Logo_RGB.jpg\",\"datePublished\":\"2022-06-23T10:01:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dem-biopharma-launches-with-70-million-financing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dem-biopharma-launches-with-70-million-financing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dem-biopharma-launches-with-70-million-financing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220623005116\\\/en\\\/1494351\\\/21\\\/DEM_Logo_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220623005116\\\/en\\\/1494351\\\/21\\\/DEM_Logo_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dem-biopharma-launches-with-70-million-financing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DEM BioPharma Launches with $70 Million Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DEM BioPharma Launches with $70 Million Financing - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/","og_locale":"en_US","og_type":"article","og_title":"DEM BioPharma Launches with $70 Million Financing - Pharma Trend","og_description":"Company will pursue untapped opportunities in the field of innate immune system checkpoints to eliminate cancer Proprietary platform leverages CRISPR screening and macrophage biology to systematically discover and drug \u201cdon\u2019t eat me\u201d (DEM) and \u201ceat me\u201d (EM) signals CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;DEM BioPharma, Inc. (DEM Bio), an immuno-oncology company developing therapies that target novel innate immune ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-23T10:01:59+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220623005116\/en\/1494351\/21\/DEM_Logo_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"DEM BioPharma Launches with $70 Million Financing","datePublished":"2022-06-23T10:01:59+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/"},"wordCount":916,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220623005116\/en\/1494351\/21\/DEM_Logo_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/","url":"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/","name":"DEM BioPharma Launches with $70 Million Financing - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220623005116\/en\/1494351\/21\/DEM_Logo_RGB.jpg","datePublished":"2022-06-23T10:01:59+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220623005116\/en\/1494351\/21\/DEM_Logo_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220623005116\/en\/1494351\/21\/DEM_Logo_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/dem-biopharma-launches-with-70-million-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"DEM BioPharma Launches with $70 Million Financing"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45409"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45409\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}